MGI Tech Launches VisiOmics in Europe and Unveils AI-Enabled Pathology Portfolio at ECP 2026
From Tissue to Answer: Integrated Solutions for Tissue and Molecular Pathology, from multiplex immunofluorescence to sample-to-result sequencing, powered by AI STOCKHOLM, Sept. 15, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.